Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $1,200,000.00 in Stock

Key Points

• Director Bonnie Bassler sold 1,500 shares on Jan. 7 at an average of $800 each for a total of $1.2M, reducing her holding by 46.83% to 1,703 shares.
• Analyst sentiment has turned more positive—Bank of America upgraded REGN to Buy with an $860 target and Truist raised its target to $820—while short interest has declined, which could amplify upside on catalysts.
• Regeneron recently beat quarterly estimates (EPS $11.83 vs. $9.73; revenue $3.75B), has a market cap of about $84.2B and a P/E near 19, and pays a $0.88 quarterly dividend (≈0.4% yield).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Bonnie Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company's stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $11.26 during trading hours on Thursday, hitting $801.01. The company had a trading volume of 1,049,280 shares, compared to its average volume of 909,947. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The firm has a market capitalization of $84.19 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 2.32 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $816.99. The firm has a 50 day simple moving average of $732.29 and a 200 day simple moving average of $624.86.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts' consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the business earned $12.46 EPS. The business's revenue for the quarter was up .9% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals's payout ratio is 8.43%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from “Underperform” to “Buy” and raised its price target to $860 (from $627), citing improving fundamentals across key products and multiple 2026 catalysts. This is one of the largest recent analyst actions and likely supports upside expectations. Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts
• Positive Sentiment: Truist raised its price target to $820 and maintained a Buy rating, signalling incremental analyst conviction and a modest upside to current levels. This adds another institutional vote of confidence for the stock. Truist raises REGN price target to $820
• Positive Sentiment: Several analysts have turned more positive and short interest has fallen, which analysts say could change the investment case for REGN — fewer shorts plus upgrades can compress downside and amplify positive moves on catalysts. Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN)
• Neutral Sentiment: A roundup of 21 analysts provides broader context on estimates and ratings — useful to gauge consensus but not a single decisive catalyst. 21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
• Neutral Sentiment: Zacks pieces highlight Regeneron’s strong history of earnings beats and compare valuation versus peers (Illumina), which helps investors assessing relative value and the likelihood of future beats but doesn't change near-term catalysts. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Comparative valuation analysis (REGN vs ILMN) offers perspective for value investors but is not an immediate driver of price action. REGN vs. ILMN: Which Stock Is the Better Value Option?

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of REGN. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $226,000. Voleon Capital Management LP grew its position in shares of Regeneron Pharmaceuticals by 85.4% during the first quarter. Voleon Capital Management LP now owns 1,244 shares of the biopharmaceutical company's stock worth $789,000 after purchasing an additional 573 shares in the last quarter. Signature Estate & Investment Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 14.4% during the first quarter. Signature Estate & Investment Advisors LLC now owns 374 shares of the biopharmaceutical company's stock worth $237,000 after purchasing an additional 47 shares in the last quarter. Finally, Caxton Associates LLP bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $531,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research analyst reports. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an "overweight" rating in a report on Wednesday, October 29th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, December 20th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an "outperform" rating in a report on Thursday, December 4th. Citigroup raised their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a "buy" rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $791.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.